Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo [published online ahead of print, 2023 Feb 2]
The patient is typically weaned (gradually takes less and less over time) off of anti-inflammatories once the DMARD has had a chance to work
it is a tool that, when used correctly, can support significant and sustained weight loss
Semaglutide for weight loss works by regulating appetite and slowing digestion, helping you stay on track with your wellness journey
However, the pharmacokinetic parameters after repeated IM administration changed slightly compared to those observed after a single IM injection, with a small decrease in C max and t 1/2 and an increase in T max
These pages should be used for navigation, not as a substitute for prescribing advice